Rockwell Med Inc Stock Price, News & Analysis

Rockwell Medical has announced that its international partner, Drogsan Pharmaceuticals, received priority review status for the Marketing Authorization application and high priority status for the GMP application of Triferic AVNU from the Turkish Medicines and Medical Devices Agency. Triferic AVNU is an iron replacement therapy aimed at maintaining hemoglobin levels in adult hemodialysis patients. Rockwell entered license and supply agreements with Drogsan in June 2021, allowing Drogsan to exclusively commercialize Triferic products in Turkey. With steady progress towards regulatory approval anticipated in 2024, Rockwell Medical is optimistic about generating revenue through these international partnerships, enhancing its growth strategy in the hemodialysis market.

Rockwell Medical, Inc. (Nasdaq: RMTI) will release its financial and operational results for Q1 2023 on May 15, 2023, at 6:00 am ET. Following the release, a live conference call and webcast will take place at 8:00 am ET. The call will discuss the company’s performance and include a Q&A session with executives, including Mark Strobeck, Ph.D., President and CEO, and Paul McGarry, CPA, SVP, Finance.

Rockwell Medical focuses on developing, manufacturing, and distributing hemodialysis products, serving as the second largest supplier of acid and bicarbonate concentrates in the U.S. The company aims to become the global leader in hemodialysis concentrates, highlighting its long-term growth strategies and commitment to quality and customer service.

Rockwell Medical, Inc. (Nasdaq: RMTI) is showcasing its hemodialysis concentrates portfolio at the National Kidney Foundation Spring Clinical Meetings from April 11-15, 2023, in Austin, Texas. The portfolio features products such as CitraPure®, Dri-Sate®, RenalPure®, and SteriLyte®, designed to improve treatment efficiency and reduce costs for dialysis providers. Rockwell is the second-largest supplier of acid and bicarbonate concentrates in the U.S., aiming to be the leading global supplier. The company focuses on delivering high-quality products and exceptional customer service to enhance the lives of patients with end-stage kidney disease. Rockwell Medical is recognized as a Great Place to Work® in 2023.

Rockwell Medical, a healthcare company focused on hemodialysis products, reported a 26.0% increase in fourth-quarter revenue, reaching $19.3 million, and an annual revenue of $72.8 million in 2022, up 17.6% year-over-year. The company significantly reduced its debt from $21.6 million to $10.0 million and lowered operational cash usage to $594,000 from $9.0 million in Q4 2021. Despite a net loss of $2.4 million for Q4 and $18.7 million for the full year, Rockwell aims for profitability with 2023 guidance projecting sales between $78.0 million and $82.0 million.

Rockwell Medical (Nasdaq: RMTI) will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion40 (DTX40) from March 28-31, 2023, in Las Vegas, Nevada. The Company is exhibiting at Booth #502, featuring products like CitraPure® Citric Acid Concentrate and Dri-Sate® Dry Acid Concentrate. Rockwell Medical is recognized as the second-largest supplier of acid and bicarbonate concentrates for dialysis in the U.S. The Company aims to enhance its offerings and provide quality service to dialysis providers while striving to become the leading global supplier of hemodialysis concentrates.

Rockwell Medical (Nasdaq: RMTI) has achieved Great Place to Work Certification™ in 2023 during its first year of participation. This recognition is based solely on employee feedback regarding workplace experiences, emphasizing high-trust environments. The certification reflects Rockwell’s commitment to providing quality products and exceptional customer service for dialysis clinics and patients. With a mission to enhance hemodialysis care, Rockwell is the second-largest supplier of dialysis concentrates in the U.S. and aims to become a global leader in this sector.

Rockwell Medical, Inc. (Nasdaq: RMTI) announced it will release its financial and operational results for Q4 and the full year ending December 31, 2022, on March 30, 2023, at 6:00 AM ET. A live conference call will follow at 8:00 AM ET, where management will discuss the results, including operational performance and future outlook. Rockwell Medical is recognized as the second largest supplier of hemodialysis products in the U.S., focusing on improving patient care through innovative healthcare solutions.

Rockwell Medical, Inc. (Nasdaq: RMTI) has signed a three-year product purchase agreement with Concerto Renal Services, the largest provider of dialysis in skilled nursing facilities in the U.S. The agreement positions Rockwell as the primary supplier of hemodialysis concentrates, contributing millions in annual revenue. The U.S. hemodialysis concentrates market is valued at $380 million, projected to grow to $500 million by 2026, driven by an increase in end-stage kidney disease patients. Rockwell aims for profitability in 2024, emphasizing its commitment to becoming a global leader in the sector.

Rockwell Medical (RMTI) has secured a multi-million dollar, three-year product purchase agreement with the largest non-profit dialysis provider in the U.S. This agreement positions Rockwell as the preferred supplier of liquid and dry acid and bicarbonate concentrates to hemodialysis facilities nationwide. CEO Mark Strobeck expressed enthusiasm, emphasizing this deal as a foundation for revenue growth and profitability by 2024. The hemodialysis concentrates market is valued at $380 million, with projections reaching $500 million by 2026 due to rising end-stage kidney disease cases. Rockwell is the second largest supplier in this vital market.